Clopidogrel monotherapy reduces MACCE risk in patients with diabetes compared to aspirin monotherapyTrial shows clopidogrel lowers heart risks for patients with diabetes

This multicenter randomized controlled trial involved 5,506 patients who underwent percutaneous coronary intervention (PCI). The study population included patients with complex coronary lesions, diabetes mellitus (DM), or a history of myocardial infarction who had completed a standard duration of dual antiplatelet therapy (DAPT). The study was designed as a prespecified analysis of the SMART-CHOICE 3 trial to evaluate the efficacy and safety of different monotherapy options following the completion of DAPT.

The study compared clopidogrel monotherapy against aspirin monotherapy. The primary outcome was the incidence of major adverse cardiac and cerebrovascular events (MACCE), defined as death from any cause, myocardial infarction, or stroke. The follow-up period for the study was 2.3 years (IQR: 1.6-3.0 years).

In the analysis of the primary outcome, patients with diabetes mellitus showed a higher risk of MACCE compared to those without diabetes. Specifically, the incidence of MACCE in patients with DM was 6.8% compared to 4.7% in non-DM patients (HR: 1.44; 95% CI: 1.10-1.87; P = 0.008). When comparing the two monotherapy options within the diabetic population, clopidogrel monotherapy was associated with a significantly lower risk of MACCE than aspirin monotherapy. The incidence of MACCE was 4.5% in the clopidogrel group versus 9.1% in the aspirin group (HR: 0.57; 95% CI: 0.38-0.86; P = 0.008).

Regarding the interaction between the presence of diabetes and the choice of antiplatelet monotherapy, the analysis found no significant interaction (P = 0.124). This suggests that the observed benefit of clopidogrel over aspirin in the diabetic population was not statistically dependent on the presence of the condition in a way that would invalidate the comparison.

Safety and tolerability were also assessed, specifically focusing on bleeding events. The study found that the risk of bleeding was comparable between clopidogrel monotherapy and aspirin monotherapy in patients with diabetes mellitus. No specific rates for serious adverse events or discontinuations were reported in the data provided.

These results contribute to the understanding of antiplatelet strategies in high-risk populations. While previous evidence has established the role of clopidogrel in reducing bleeding risk in acute coronary syndromes, this study specifically highlights a superior outcome for clopidogrel over aspirin in the context of diabetes mellitus following PCI. The findings suggest that for patients who have completed standard DAPT and have a diagnosis of DM, clopidogrel may be a more effective monotherapy option.

Methodological limitations were not reported. However, it is important to note that this study is a prespecified analysis of the SMART-CHOICE 3 trial. The clinical implication for practice is that clopidogrel monotherapy is associated with a lower risk of MACCE compared with aspirin monotherapy in DM patients who completed standard DAPT after PCI, without increased rates of bleeding. Questions remain regarding the long-term durability of this effect and the specific impact on different subtypes of coronary disease.